Coupling of Epidermal Growth Factor (EGF) with the Antiproliferative Activity of cAMP Induces Neuronal Differentiation*

  1. Melanie D. Mark and
  2. Daniel R. Storm
  1. From the Department of Pharmacology, University of Washington, Seattle, Washington 98195

    Abstract

    Nerve growth factor (NGF) functions as a progression factor with both mitogenic and antimitogenic activities. When PC12 cells are treated with NGF, they advance to the G1stage of the cell cycle before they differentiate. The correlation between cessation of proliferation and differentiation suggests that the antimitotic activity of NGF may be obligatory for differentiation. Although epidermal growth factor- (EGF) and NGF-treated PC12 cells share several common properties, including activation of the mitogen-activated protein (MAP) kinase pathway and induction of immediate early genes, EGF is mitogenic for PC12 cells and does not normally stimulate differentiation. However, combinations of EGF and low levels of cAMP stimulate differentiation even though neither agent alone does (Mark, M. D., Liu, Y., Wong, S. T., Hinds, T. R., and Storm, D.R. (1995) J. Cell Biol. 130, 701–710). Since EGF is mitogenic for PC12 cells and differentiation may not occur until proliferation is inhibited, differentiation caused by cAMP and EGF may be due to the antiproliferative activity of cAMP. To test this hypothesis, we examined the effect of EGF or combinations of EGF and cAMP on PC12 cell proliferation. EGF alone stimulated proliferation of PC12 cells and increased the levels of several cell cycle progression factors including cdk2, cdk4, and cyclin B1. Cyclic AMP inhibited the EGF-stimulated increases in cell cycle progression factors as well as proliferation. Other antiproliferative agents including rapamycin, mimosine, and nitric oxide agonists also synergized with EGF to stimulate differentiation. These data indicate that the coupling of antiproliferative signals with EGF modifies the biological properties of EGF and converts it to a differentiating growth factor.

    Footnotes

    • * This work was supported by National Institutes of Health Grant NS20498.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • To whom correspondence should be addressed. Tel.: 206-543-7028; Fax: 206-685-3822.

    • 1 The abbreviations used are: NGF, nerve growth factor; EGF, epidermal growth factor; MAP, mitogen-activated protein; HRP, horseradish peroxidase.

      • Received February 11, 1997.
      • Revision received April 11, 1997.
    « Previous | Next Article »Table of Contents
    • Advertisement
    • Advertisement
    Advertisement